{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:20:59Z","timestamp":1768821659459,"version":"3.49.0"},"reference-count":19,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2021.2348","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T11:29:08Z","timestamp":1625743748000},"source":"Crossref","is-referenced-by-count":7,"title":["Tumor protein p53 mutation in archived tumor samples from a 12\u2011year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long\u2011term survival with DeltaRex\u2011G: A case report and literature review"],"prefix":"10.3892","volume":"15","author":[{"given":"Michael","family":"Morse","sequence":"first","affiliation":[{"name":"Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sant","family":"Chawla","sequence":"additional","affiliation":[{"name":"Cancer Center of Southern California, Santa Monica, CA 90403, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Wong","sequence":"additional","affiliation":[{"name":"Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Bruckner","sequence":"additional","affiliation":[{"name":"Bruckner Oncology, Bronx, NY 10469, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Hall","sequence":"additional","affiliation":[{"name":"Delta Next\u2011Gene, LLC, Santa Monica, CA 90405, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlinda","family":"Gordon","sequence":"additional","affiliation":[{"name":"Cancer Center of Southern California, Santa Monica, CA 90403, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"key20210810115907_b1-mco-0-0-02348"},{"issue":"8","key":"key20210810115907_b2-mco-0-0-02348","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"key20210810115907_b3-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus Gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"key20210810115907_b4-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.omto.2018.12.005","article-title":"A phase I\/II clinical study on the safety, efficacy, and therapeutic potential of intravenous DeltaRex-G: A tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer","volume":"12","author":"Chawla","year":"2019","journal-title":"Mol Ther Oncol"},{"key":"key20210810115907_b5-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.omto.2018.11.002","article-title":"Exploiting oncogenic drivers along the CCNG1 pathway for cancer therapy and gene therapy","volume":"11","author":"Al-Shihabi","year":"2018","journal-title":"Mol Ther Oncolytics"},{"issue":"5712","key":"key20210810115907_b6-mco-0-0-02348","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13392-y","article-title":"Functional significance of U2AF1 S34F mutations in lung adenocarcinomas","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"issue":"42","key":"key20210810115907_b7-mco-0-0-02348","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050042","article-title":"KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer","volume":"9","author":"Cicenas","year":"2017","journal-title":"Cancers (Basel)"},{"key":"key20210810115907_b8-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1046\/j.1365-2443.2002.00564.x","article-title":"Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein","volume":"7","author":"Kimura","year":"2002","journal-title":"Genes Cells"},{"key":"key20210810115907_b9-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcp.20689","article-title":"The p53 tumor suppressor participates in multiple cell cycle checkpoints","volume":"209","author":"Giono","year":"2006","journal-title":"J Cell Physiol"},{"key":"key20210810115907_b10-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3892\/mco.2018.1657","article-title":"Cell cycle checkpoint control: The cyclin G1\/Mdm2\/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy-a review of molecular mechanisms for oncologists","volume":"9","author":"Gordon","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"key20210810115907_b11-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/s1534-5807(02)00182-x","article-title":"Cyclin G: A regulator of the p53-Mdm2 network","volume":"2","author":"Chen","year":"2002","journal-title":"Dev Cell"},{"key":"key20210810115907_b12-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1053\/jhep.2003.50137","article-title":"Reduced hepatic tumor incidence in Cyclin G1-deficient mice","volume":"37","author":"Jensen","year":"2003","journal-title":"Hepatology"},{"issue":"a001008","key":"key20210810115907_b13-mco-0-0-02348","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: Origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20210810115907_b14-mco-0-0-02348","first-page":"3343","article-title":"Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct","volume":"60","author":"Gordon","year":"2000","journal-title":"Cancer Res"},{"key":"key20210810115907_b15-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/104303401750061258","article-title":"Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice","volume":"12","author":"Gordon","year":"2001","journal-title":"Hum Gene Ther"},{"key":"key20210810115907_b16-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/mt.2008.29","article-title":"Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer","volume":"16","author":"Galanis","year":"2008","journal-title":"Mol Ther"},{"key":"key20210810115907_b17-mco-0-0-02348","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/mt.2009.126","article-title":"Phase I\/II and phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma","volume":"17","author":"Chawla","year":"2009","journal-title":"Mol Ther"},{"issue":"1024","key":"key20210810115907_b18-mco-0-0-02348","article-title":"An advanced phase 1\/2 study using an XC-targeted gene therapy vector for chemotherapy resistant sarcoma","volume":"3","author":"Chawla","year":"2016","journal-title":"Sarcoma Res Int"},{"key":"key20210810115907_b19-mco-0-0-02348","author":"Bruckner"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T09:18:31Z","timestamp":1628587111000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2021.2348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,7,8]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2021.2348","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"article-number":"186"}}